This Ervebo market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historic period can be attributed to factors such as a rise in the number of patients, greater involvement in R&D initiatives, increased demand for treatments and novel therapies, higher investments in vaccine development, and greater consumption of animal fats.
Growth during the market's forecast period can be attributed to growing awareness of travel vaccinations, a rising incidence of viral infections, increased demand for viral vaccines, more government support, and a higher prevalence of zoonotic diseases. Key trends during this period include technological innovations, product launches and approvals, advancements in medical technologies, and geographic market expansions.
The growing incidence of viral infections is expected to drive the expansion of the ervebo market in the future. A viral infection occurs when a virus invades and replicates within a host's cells, leading to diseases that vary in severity depending on the virus and the host's immune response. The rise in viral infections is largely attributed to global travel, which facilitates the rapid spread of viruses across regions, and climate change, which alters ecosystems and creates conditions that allow new viruses to emerge. Ervebo helps prevent viral infections by vaccinating at-risk populations during outbreaks, typically through ring vaccination strategies aimed at controlling the spread of the Zaire ebolavirus. For example, between September 20, 2022, and January 10, 2023, the World Health Organization reported identifying 4,793 contacts and 11,025 alerts. Of these, 8,088 alerts (73%) were investigated, and 7,382 (67%) were confirmed as suspected cases of Ebola disease caused by the Sudan ebolavirus. Therefore, the rising incidence of viral infections is fueling the growth of the ervebo market.
Increasing investments in healthcare are expected to boost the future growth of the ervebo market. Healthcare investments refer to financial resources allocated to healthcare entities, technologies, services, and innovations. The rise in healthcare investments is driven by the increasing demand for chronic disease management from aging populations and funding for advanced technologies such as telemedicine and AI to improve healthcare services. These investments play a vital role in the development and success of the Ervebo Ebola vaccine by supporting research, clinical trials, production, and distribution. For instance, healthcare expenditure in the UK grew by 5.6% in nominal terms from 2022 to 2023, a notable increase compared to the 0.9% growth seen in 2022, according to the Office for National Statistics. Consequently, the rise in healthcare investments is supporting the growth of the ervebo market.
A key trend in the ervebo market is the pursuit of regulatory drug approvals to expand its availability and enhance its global reach. Regulatory approvals are granted by national or international health authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), following an evaluation process to authorize a new drug or vaccine for public use. For example, in August 2023, Merck & Co. Inc. received FDA approval for ERVEBO (Ebola Zaire Vaccine, Live) for use in children aged 12 months and older. This vaccine has shown to be 100% effective when administered more than ten days prior to exposure to the Ebola virus. As a live recombinant viral vaccine, it triggers an immune response without causing the disease. This approval was significant in addressing the urgent need for vaccination in younger populations at risk of Ebola virus disease, especially given that children made up a large proportion of cases in previous outbreaks.
The key company operating in the ervebo market is Merck & Co. Inc.
North America was the largest region in the ervebo market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in ervebo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ervebo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Ervebo is a recombinant, live vaccine designed to protect against Ebola virus disease caused by the Zaire ebolavirus species. Administered as a single-dose injection, it has played a crucial role in controlling outbreaks, especially through ring vaccination strategies in affected areas.
The primary clinical indications for ervebo include general immunization and geographically targeted vaccination. General immunization refers to the widespread distribution of vaccines to protect against common infectious diseases. It is distributed through hospital pharmacies and retail pharmacies, serving various end users, including adults and the elderly.
The ervebo market research report is one of a series of new reports that provides ervebo market statistics, including ervebo industry global market size, regional shares, competitors with an ervebo market share, detailed ervebo market segments, market trends and opportunities, and any further data you may need to thrive in the ervebo industry. This ervebo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ervebo market consists of sales of products including pre-filled vaccine syringes, cold chain storage solutions, vaccination kits, and training and education materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historic period can be attributed to factors such as a rise in the number of patients, greater involvement in R&D initiatives, increased demand for treatments and novel therapies, higher investments in vaccine development, and greater consumption of animal fats.
Growth during the market's forecast period can be attributed to growing awareness of travel vaccinations, a rising incidence of viral infections, increased demand for viral vaccines, more government support, and a higher prevalence of zoonotic diseases. Key trends during this period include technological innovations, product launches and approvals, advancements in medical technologies, and geographic market expansions.
The growing incidence of viral infections is expected to drive the expansion of the ervebo market in the future. A viral infection occurs when a virus invades and replicates within a host's cells, leading to diseases that vary in severity depending on the virus and the host's immune response. The rise in viral infections is largely attributed to global travel, which facilitates the rapid spread of viruses across regions, and climate change, which alters ecosystems and creates conditions that allow new viruses to emerge. Ervebo helps prevent viral infections by vaccinating at-risk populations during outbreaks, typically through ring vaccination strategies aimed at controlling the spread of the Zaire ebolavirus. For example, between September 20, 2022, and January 10, 2023, the World Health Organization reported identifying 4,793 contacts and 11,025 alerts. Of these, 8,088 alerts (73%) were investigated, and 7,382 (67%) were confirmed as suspected cases of Ebola disease caused by the Sudan ebolavirus. Therefore, the rising incidence of viral infections is fueling the growth of the ervebo market.
Increasing investments in healthcare are expected to boost the future growth of the ervebo market. Healthcare investments refer to financial resources allocated to healthcare entities, technologies, services, and innovations. The rise in healthcare investments is driven by the increasing demand for chronic disease management from aging populations and funding for advanced technologies such as telemedicine and AI to improve healthcare services. These investments play a vital role in the development and success of the Ervebo Ebola vaccine by supporting research, clinical trials, production, and distribution. For instance, healthcare expenditure in the UK grew by 5.6% in nominal terms from 2022 to 2023, a notable increase compared to the 0.9% growth seen in 2022, according to the Office for National Statistics. Consequently, the rise in healthcare investments is supporting the growth of the ervebo market.
A key trend in the ervebo market is the pursuit of regulatory drug approvals to expand its availability and enhance its global reach. Regulatory approvals are granted by national or international health authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), following an evaluation process to authorize a new drug or vaccine for public use. For example, in August 2023, Merck & Co. Inc. received FDA approval for ERVEBO (Ebola Zaire Vaccine, Live) for use in children aged 12 months and older. This vaccine has shown to be 100% effective when administered more than ten days prior to exposure to the Ebola virus. As a live recombinant viral vaccine, it triggers an immune response without causing the disease. This approval was significant in addressing the urgent need for vaccination in younger populations at risk of Ebola virus disease, especially given that children made up a large proportion of cases in previous outbreaks.
The key company operating in the ervebo market is Merck & Co. Inc.
North America was the largest region in the ervebo market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in ervebo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ervebo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Ervebo is a recombinant, live vaccine designed to protect against Ebola virus disease caused by the Zaire ebolavirus species. Administered as a single-dose injection, it has played a crucial role in controlling outbreaks, especially through ring vaccination strategies in affected areas.
The primary clinical indications for ervebo include general immunization and geographically targeted vaccination. General immunization refers to the widespread distribution of vaccines to protect against common infectious diseases. It is distributed through hospital pharmacies and retail pharmacies, serving various end users, including adults and the elderly.
The ervebo market research report is one of a series of new reports that provides ervebo market statistics, including ervebo industry global market size, regional shares, competitors with an ervebo market share, detailed ervebo market segments, market trends and opportunities, and any further data you may need to thrive in the ervebo industry. This ervebo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ervebo market consists of sales of products including pre-filled vaccine syringes, cold chain storage solutions, vaccination kits, and training and education materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Ervebo Market Characteristics4. Ervebo Market Trends and Strategies5. Ervebo Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Ervebo Pricing Analysis & Forecasts30. Global Ervebo Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Ervebo Market32. Recent Developments in the Ervebo Market
3. Ervebo Market Biologic Drug Characteristics
6. Global Ervebo Growth Analysis and Strategic Analysis Framework
8. Ervebo Market Segmentation
9. Global Ervebo Epidemiology of Clinical Indications
10. Ervebo Market Regional and Country Analysis
11. Asia-Pacific Ervebo Market
12. China Ervebo Market
13. India Ervebo Market
14. Japan Ervebo Market
15. Australia Ervebo Market
16. South Korea Ervebo Market
17. Western Europe Ervebo Market
18. UK Ervebo Market
19. Germany Ervebo Market
20. France Ervebo Market
21. Eastern Europe Ervebo Market
22. North America Ervebo Market
23. USA Ervebo Market
24. Canada Ervebo Market
25. South America Ervebo Market
26. Middle East Ervebo Market
27. Africa Ervebo Market
28. Ervebo Market Competitive Landscape and Company Profiles
29. Global Ervebo Market Pipeline Analysis
33. Ervebo Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Ervebo Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ervebo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ervebo? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ervebo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: General Immunization; Geographically Targeted Vaccination2) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies
3) by End User: Adult; Geriatric
Key Companies Mentioned: Merck & Co. Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
